Tarsus Pharmaceuticals, Inc. TARS
Sales up 146.7%, free cash flow up to -$22.3M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (35, from the latest 10-K and 10-Q)
- EPS (ttm)
- -15.86
- Sales (ttm)
- 682.2M
- Net income (ttm)
- -702.2M
- Sales growth
- +147%
- EPS growth
- -
- Sales Q/Q
- +63.9%
- Free cash flow
- 32.4M
- Gross margin
- -
- Oper. margin
- -102.0%
- Net margin
- -102.9%
- FCF margin
- 4.8%
- ROE
- n/m
- ROA
- -138.9%
- R&D / sales
- 14.3%
- Dividend
- 0.00
- Debt/Eq
- 0.70
- Curr. ratio
- 1.96
- Cash
- 136.5M
- Op. cash flow (ttm)
- 49.9M
- EBITDA
- -70.1M
- EBITDA margin
- -15.5%
- Net debt
- -63.6M
- Quick ratio
- 1.94
- Interest cover
- -7.94
- FCF after stock pay
- -64.0M
- Oper. margin low 5y
- -820.5%
- Stock pay / sales
- 9.2%
- Shares out.
- 49.3M
- Shares Y/Y
- +11.1%
- Book / share
- 2.11
- Cash / share
- 2.77
- Sales / share
- 13.84
- Asset turnover
- 1.35
- Days sales out.
- 69
- Sales 3Y CAGR
- +159%
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2020 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
TARS against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals, Inc. | $682.2M | +147% | - | -102.9% | - | 4.8% | 0.70 |
| RARE Ultragenyx Pharmaceutical Inc. | $730.0M | +20.2% | - | -71.8% | - | -60.5% | - |
| TMDX TransMedics Group, Inc. | $727.6M | +37.1% | 58.6% | 19.9% | 26.2% | 6.1% | - |
| GKOS GLAUKOS Corp | $690.3M | +32.3% | 64.8% | -24.6% | -23.7% | 5.2% | - |
| MIRM Mirum Pharmaceuticals, Inc. | $670.8M | +54.7% | - | -134.8% | - | -40.8% | - |
| UFPT UFP Technologies Inc | $649.5M | +19.5% | 28.9% | 11.8% | 15.8% | - | 0.20 |
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2021 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-102.9% vs 6.8%
-
Return on equity below 15%-675.0%
-
A profit in 0 of 6 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -7.9× interest expense
-
Debt smaller than equityDebt / equity 0.70 on the latest balance sheet (peer median 0.69)
-
Current assets cover current liabilitiesCurrent ratio 1.96
-
More cash than debtNet cash $297.2M
Cash and shareholders
-
Free cash flow positive in 1 of 6 years−$22.3M last year
-
Share count up over 5 years+573.1%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
TARS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 8. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| Product sales, net | 451.4M | 100.0% | +151% |
| License fees and collaboration revenue | 0 | 0.0% | -100% |
10-K 0001819790-26-000019, segment and revenue notes (XBRL).
Income statement
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 57.0M | 25.8M | 17.4M | 183.0M | 451.4M |
| R&D | - | 3.2M | 18.8M | 41.7M | 42.6M | 50.3M | 53.4M | 64.3M |
| SG&A | - | 1.1M | 8.2M | 25.4M | 44.9M | 108.7M | 237.3M | 427.3M |
| Operating income | - | -4.3M | -27.0M | -12.2M | -62.7M | -143.2M | -120.6M | -71.0M |
| Interest expense | - | - | - | 0 | 2.2M | 3.3M | 7.8M | 8.9M |
| Pretax income | - | - | -26.8M | -13.8M | -62.1M | -135.9M | -115.6M | -64.4M |
| Income tax | - | 1K | 1K | 55K | -4K | 0 | 0 | 2.1M |
| Net income | -1.3M | -4.7M | -26.8M | -13.8M | -62.1M | -135.9M | -115.6M | -66.4M |
| EPS (diluted) | - | -1.98 | -4.32 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 |
| Diluted shares | - | - | 6.2M | 20.6M | 24.6M | 29.4M | 37.6M | 41.8M |
| Depreciation & amortization | - | 37K | 100K | 300K | 326K | 744K | 685K | 855K |
| EBITDA | - | -4.3M | -26.9M | -11.9M | -62.4M | -142.4M | -119.9M | -70.1M |
| Operating margin | - | - | - | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Net margin | - | - | - | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| Revenue growth | - | - | - | - | -54.7% | -32.4% | +949% | +147% |
Balance sheet
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash | 2.4M | 58.0M | 168.1M | 171.3M | 71.7M | 224.9M | 94.8M | 183.6M |
| Short-term investments | - | - | 0 | 483K | 145.4M | 2.5M | 196.6M | 233.6M |
| Receivables | - | - | 0 | 0 | 0 | 16.6M | 46.8M | 85.1M |
| Inventory | - | - | - | - | 0 | 3.1M | 2.6M | 4.4M |
| Current assets | - | 58.0M | 170.7M | 176.0M | 225.4M | 256.1M | 356.7M | 522.8M |
| Property & equipment | - | 154K | 548K | 755K | 957K | 1.5M | 2.3M | 11.7M |
| Other intangible assets | - | - | - | - | 0 | 3.9M | 8.3M | 7.4M |
| Total assets | - | 58.3M | 172.0M | 178.9M | 227.9M | 265.5M | 377.0M | 562.2M |
| Accounts payable | - | - | - | - | - | - | 9.4M | 16.4M |
| Current liabilities | - | 819K | 5.4M | 11.5M | 15.4M | 36.9M | 80.6M | 135.7M |
| Total debt | - | - | - | 0 | 19.4M | 29.8M | 71.8M | 72.4M |
| Total liabilities | - | 919K | 6.0M | 12.2M | 35.0M | 68.5M | 152.5M | 218.7M |
| Shareholders' equity | -1.4M | -6.0M | 166.0M | 166.7M | 192.9M | 197.0M | 224.5M | 343.4M |
| Retained earnings | - | -6.0M | -32.8M | -46.7M | -108.8M | -244.7M | -360.2M | -426.6M |
Cash flow
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | - | -3.7M | -21.1M | 3.7M | -49.0M | -117.5M | -83.0M | -12.5M |
| Capital spending | - | 175K | 456K | 586K | 506K | 1.5M | 1.6M | 9.9M |
| Free cash flow | - | -3.8M | -21.6M | 3.2M | -49.5M | -119.0M | -84.6M | -22.3M |
| Stock-based pay (added back) | - | 18K | 839K | 8.5M | 13.5M | 19.8M | 27.8M | 41.7M |
| Free cash flow after stock pay | - | -3.9M | -22.4M | -5.3M | -63.0M | -138.8M | -112.4M | -64.0M |
| Debt raised | - | - | - | - | 20.0M | 10.0M | 75.0M | 0 |
| Investing cash flow | - | -175K | -456K | -586K | -144.6M | 140.6M | -199.2M | -42.1M |
| Financing cash flow | - | 59.4M | 131.8M | 21K | 94.0M | 130.2M | 154.7M | 143.4M |
| Dividend per share | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Stock-based pay and leases
From EDGAR| FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | - | 18K | 839K | 8.5M | 13.5M | 19.8M | 27.8M | 41.7M |
| Stock-based pay / revenue | - | - | - | 14.8% | 52.1% | 113.7% | 15.2% | 9.2% |
| Operating lease cost | - | 100K | 208K | 385K | 569K | 705K | 835K | 1.5M |
| Operating lease cash paid | - | - | - | - | 680K | 884K | 799K | 858K |
| Right-of-use assets | - | 126K | 688K | 1.1M | 575K | 1.9M | 552K | 10.1M |
| Operating lease liabilities | - | 164K | 831K | 1.2M | 889K | 1.9M | 608K | 10.6M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.